Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details)

v3.22.0.1
Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Anti-dilutive securities      
Warrant issued to purchase common stock 2,117,094 2,117,094 2,118,094
Private Placement      
Anti-dilutive securities      
Warrant issued to purchase common stock 2,828,125 2,828,125  
First Draw of Loan Agreement      
Anti-dilutive securities      
Warrant issued to purchase common stock 27,548 27,548  
Second Draw on Loan Agreement      
Anti-dilutive securities      
Warrant issued to purchase common stock 17,389 17,389